Mountaingate Announces Strategic Combination of Argentum Medical with BioDerm

February 2023

Bio Derm

Mountaingate Capital (“Mountaingate”) a Denver, Colorado based private equity firm that has successfully invested in the healthcare and medical device sectors for over 20 years, announced that it has completed the strategic combination of Argentum Medical, a medical device leader and pioneer of silver-plated nylon technology with BioDerm, a leading provider of disposable medical devices and wound care products. The combination of Argentum and BioDerm creates a powerful portfolio of innovative proprietary products and services focused on infection prevention and advanced wound care solutions.

Mountaingate facilitated the transaction through its existing investment in BioDerm and new investment in the combined entity.  Mountaingate Capital specializes in building and empowering companies with strong growth potential and engaged leadership teams through its customer-centric buy-and-build strategy.

Raul Brizuela, CEO of Argentum Medical and Argentum Medical’s majority shareholder prior to receiving a growth investment from Shore Capital Partners in 2017, will serve as CEO of the combined platform and be added to the Board of Directors. The leadership team will be comprised of executives from both companies.

“The combination of BioDerm and Argentum Medical creates a platform with leading infection prevention products marked by a focus on innovation.  With added scale and resources, this strategic alignment will enable both companies to more effectively serve existing and new customers and patients to improve clinical outcomes and quality of life” said Raul Brizuela. “I am particularly excited about the great talent and experience that each company brings to the platform, enabling us to quickly integrate and increase the pace of growth investments.”

“The combination of Argentum and BioDerm accelerates our strategy to innovate patient care with sophisticated technologies and expand our growth in the wound-care and international markets,” said Stew Fisher, Managing Director of Mountaingate Capital.   “The two companies share a common culture focused on improving patient outcomes through   innovation and ingenuity, while also providing industry leading levels of customer support.”

Following the combination, later in 2023, the combined company will look to rebrand and establish a new name that reflects the strengths of the Argentum and BioDerm portfolios of products.  The combined company will continue to invest in and market its leading brands including Silverlon, TheraBond 3D, Men’s Liberty, CathGrip®, FreeDerm®, BioPlus™, Anasept and Silver-Sept.


Argentum Medical pioneered the use of silver-plated nylon. Specializing in the development of innovative products made from silver-plated nylon, the companies continue to explore new applications and markets for SILVERLON® technology in keeping with their corporate mission to improve clinical outcomes. For more information, please visit and


BioDerm is one of the nation’s leading manufacturers of proprietary hydrocolloid products for urinary management, securement, infection control and skin protection.  The Company also provides custom wound care kits to patients with ventricular assist devices installed due to heart failure.  BioDerm challenges accepted inferior standards of care by creating and distributing products that reduce infection rates, add comfort and reliability, and vastly improve quality of life. For more information, please visit


Mountaingate Capital is a Denver-based private equity firm investing in the marketing services, business services, specialty distribution and specialty manufacturing sectors. Mountaingate specializes in building and empowering companies with strong growth potential and engaged leadership teams. Mountaingate’s focus on organic growth coupled with its proven customer-centric buy-and-build approach and shared equity ownership with management creates more value for the end customer, while forging stronger, more collaborative, and more successful partnerships with management teams. Mountaingate targets investments in new platform companies with $5 million to $25 million of EBITDA, as well as add-on acquisitions of any size. For more information on Mountaingate, please visit